Hepatitis C Management in Special Populations

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 8/17/18 (What's New)

Summary

  • HCV is a major cause of cirrhosis and hepatocellular carcinoma worldwide[Ponziani 2011]
  • In the US, HCV is a leading cause of liver-related death and the most common indication for liver transplantation[Fayek 2016; CDC HCV FAQ]
  • Effective HCV therapies are available; the presence of comorbidities, coinfections, and other special patient circumstances may complicate their use in clinical practice

Action required

Keywords: Hepatitis C, Hepatitis C-Special Populations

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.